Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Genkyotex

- PMLiVE

GSK shares promising phase 3 results for linerixibat in PBC-related itch

Pruritus is experienced by up to 90% of patients with the rare liver disease

- PMLiVE

Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis

The rare liver disease affects approximately 100,000 people in the US

- PMLiVE

Calliditas bets on PBC drug in Genkyotex buyout

Calliditas will acquire 62.7% of company for an initial €20.3m

- PMLiVE

Swedish biotech Calliditas signs China licensing deal for autoimmune candidate

IgA nephropathy more common in China

- PMLiVE

CHMP backs Intercept’s rare liver disease drug

Ocaliva on track for EU approval as analysts predict blockbuster sales

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links